A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, DoseEscalation Study to Evaluate the Safety, Reactogenicity, andImmunogenicity of mRNA-1345, an mRNA Vaccine TargetingRespiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years,Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged= 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2024
This article has no abstract
Epistemonikos ID: 802d5c2c4f6c4655e88b453b651a0d9a24d346d7
First added on: Apr 17, 2025